Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

Megan C. Turner, Kara Rossfeld, April K.S. Salama, Douglas Tyler, Georgia Beasley

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT. Expert opinion: While the 3 novel agents reviewed here have potential for use in melanoma, optimal utilization will occur once a more personalized approach incorporating genomic, proteomic, and immunologic data guides therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)487-495
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number5
DOIs
StatePublished - Mar 24 2017

Fingerprint

Melanoma
Mutation
Mitogen-Activated Protein Kinase Kinases
Expert Testimony
Therapeutics
Proteomics
encorafenib
masitinib
MEK162

Keywords

  • BRAF
  • c-kit
  • MEK
  • Melanoma
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? / Turner, Megan C.; Rossfeld, Kara; Salama, April K.S.; Tyler, Douglas; Beasley, Georgia.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 5, 24.03.2017, p. 487-495.

Research output: Contribution to journalReview article

@article{b57fb06594fe49cbbdb41d28bf8881c0,
title = "Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?",
abstract = "Introduction: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT. Expert opinion: While the 3 novel agents reviewed here have potential for use in melanoma, optimal utilization will occur once a more personalized approach incorporating genomic, proteomic, and immunologic data guides therapeutic decisions.",
keywords = "BRAF, c-kit, MEK, Melanoma, targeted therapy",
author = "Turner, {Megan C.} and Kara Rossfeld and Salama, {April K.S.} and Douglas Tyler and Georgia Beasley",
year = "2017",
month = "3",
day = "24",
doi = "10.1080/14656566.2017.1299710",
language = "English (US)",
volume = "18",
pages = "487--495",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

AU - Turner, Megan C.

AU - Rossfeld, Kara

AU - Salama, April K.S.

AU - Tyler, Douglas

AU - Beasley, Georgia

PY - 2017/3/24

Y1 - 2017/3/24

N2 - Introduction: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT. Expert opinion: While the 3 novel agents reviewed here have potential for use in melanoma, optimal utilization will occur once a more personalized approach incorporating genomic, proteomic, and immunologic data guides therapeutic decisions.

AB - Introduction: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT. Expert opinion: While the 3 novel agents reviewed here have potential for use in melanoma, optimal utilization will occur once a more personalized approach incorporating genomic, proteomic, and immunologic data guides therapeutic decisions.

KW - BRAF

KW - c-kit

KW - MEK

KW - Melanoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85016232821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016232821&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1299710

DO - 10.1080/14656566.2017.1299710

M3 - Review article

C2 - 28277830

AN - SCOPUS:85016232821

VL - 18

SP - 487

EP - 495

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -